Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
| Status: | Archived |
|---|---|
| Conditions: | Skin and Soft Tissue Infections, Nephrology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2010 |
A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
This study will determine the efficacy, safety, tolerability and the PK profile of BAF312, a
novel immunomodulator, in polymyositis and dermatomyositis patients that are not responsive
to traditional immunosuppressive and/or corticosteroid therapy. The study will consist of a
12 week, randomized, placebo controlled period, followed by another 12 weeks where all
subjects will receive BAF312 treatment.
We found this trial at
2
sites
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Click here to add this to my saved trials
850 Boylston Street
Chestnut Hill, Massachusetts 02467
Chestnut Hill, Massachusetts 02467
1-800-BWH-9999
Brigham & Women's Hospital Women's Health Center At Brigham and Women
Click here to add this to my saved trials